BrightPath Biotherapeutics Co., Ltd.

TSE:4594 Stock Report

Market Cap: JP¥4.2b

BrightPath Biotherapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Kenichi Nagai

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure15.3yrs
CEO ownership0.3%
Management average tenureno data
Board average tenure8.8yrs

Recent management updates

Recent updates


CEO

Kenichi Nagai (53 yo)

15.3yrs

Tenure

Mr. Kenichi Nagai has been the Chief Executive Officer of BrightPath Biotherapeutics Co., Ltd. (Formerly, GreenPeptide Co., Ltd.) since 2011. Mr. Nagai served as Chief Financial Officer and Manager of Admi...


Board Members

NamePositionTenureCompensationOwnership
Kenichi Nagai
CEO & Representative Director15.3yrsno data0.34%
¥ 14.2m
Yoichi Takeshita
CFO & Directorless than a yearno datano data
Norihiro Nakamura
GM of Drug Discovery Research Department & Director5.8yrsno datano data
Hirotaka Takeuchi
Independent External Director8.8yrsno datano data
Akira Yamada
Director20.3yrsno data0.26%
¥ 10.9m
Taketoshi Abe
External Auditor14.8yrsno datano data
Yoshiyasu Yamaguchi
External Auditor8.8yrsno datano data
Tsutomu Kishino
Internal Auditor5.3yrsno datano data

8.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 4594's board of directors are considered experienced (8.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.